Marinus Pharmaceuticals (MRNS) announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV), the Magnolia Study, and oral dose, the Amaryllis Study, in women with postpartum depression (PPD). Based on the positive results, the company is advancing both studies into the next phase of development to evaluate IV and oral dose regimens.
Postpartum Depression (PPD)
PPD is a mood disorder that affects about 15% of women within the first year following childbirth. Common symptoms include: feelings of extreme sadness, hopelessness, suicidal ideation, anxiety and fatigue . . .